Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2017 call → NO1. The user asks to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling, with three specific conditions. 2. Analyze the transcript for the three conditions: * Condition 1: Management speaks about counterparties' business as part of its own. Does management describe what identifiable counterparties (customers, partners, etc.) are up to—their ramps, launches, rollouts, adoption curves—as the driver of the company's coming activity? * Condition 2: The company is already inside that growth, not bidding for it. Is the company already supplying, serving, embedded in, or contracted to those counterparties with current activity flowing? * Condition 3: The counterparties' trajectory is early and large relative to the company. Does management convey that these parties are still in the early or intensifying part of what they are doing, with more ahead? 3. Review the transcript content: * The call discusses Hologic's Q4 2017 results and 2018 guidance. * Management discusses its own divisions: Diagnostics, Breast Health, Surgical, Skeletal, and Medical Aesthetics (Cynosure). * For Diagnostics, they discuss the Panther system, its installed base, and assay revenue. They mention "increasing usage of our Aptima women's health assays and our growing menu of virology tests" and "average Panther system generated more than $200,000 of assay revenue". They discuss FDA clearance for respiratory assays on Panther Fusion. This is about their own product adoption and installed base, not specifically narrating a counterparty's own expansion (like a lab network's build-out) as the driver. They talk about "global growth" and "international growth" but not a specific counterparty's trajectory. * For Breast Health, they discuss 3D shipments, market share, backlog, and new products (3Dimensions, 3D Performance, Brevera). They mention "we had a record quarter of 3D shipments" and "we continued to gain market share". This is about their own sales and market penetration, not a specific counterparty's expansion. * For Surgical, they discuss MyoSure and NovaSure sales, and new products like MyoSure MANUAL. Again, this is about their own product performance and market expansion. * For Medical Aesthetics (Cynosure), they discuss the salesforce, leadership changes, and new products (SculpSure submental, RF platform).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.